Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced that EYLEA (aflibercept) Injection has been recommended for approval by the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of visual impairment due to macular edema secondary to central or branch retinal vein occlusion. On Friday shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) closed at $420.21. Company’s sales growth for last 5 years was 54.60% and EPS growth for next 5 years is recorded as 19.71%.
Former Qualcomm Inc. (NASDAQ:QCOM) Chief Executive Officer Paul E. Jacobs, who stepped down in March, and his replacement Steven M. Mollenkopf were paid a combined $117.7 million in the company’s latest fiscal year as part of a plan to retain its employees. QUALCOMM, Inc. (NASDAQ:QCOM) in last trading activity increased 0.37% to close at $72.18. Company weekly performance is 1.11% while its quarterly performance stands at -2.29%. QUALCOMM, Inc. (NASDAQ:QCOM) is -10.95% away from its 52 week high.
On Jan 16, Colgate-Palmolive Company (NYSE:CL) will provide a live webcast of its 2014 fourth quarter and year-end earnings conference call on Thursday, January 29, 2015, at 11:00 a.m. ET. The call will be hosted by Chairman, President and CEO, Ian Cook, and Senior Vice President – Investor Relations, Bina Thompson. On last trading day Colgate-Palmolive Co. (NYSE:CL) fell -3.14% to close at $67.14. Its volatility for the week is 1.92% while volatility for the month is 1.40%. CL’s sales growth for past 5 years was 2.60% and its EPS growth for past 5 years was 5.40%. Colgate-Palmolive Co. (NYSE:CL) monthly performance is -3.93%.
On January 21, Avista (NYSE: AVA) and all other parties involved in the company’s natural gas general rate filing have reached a settlement agreement that, if approved by the Public Utility Commission of Oregon (PUC), would conclude the proceedings for the general rate request filed on Sept. 2, 2014. If the settlement agreement is approved, new rates would take effect on March 1, 2015. Avista Corp. (NYSE:AVA) has 0.90% insider ownership while its institutional ownership stands at 66.90%. In last trading activity company’s stock closed at $37.92.
Zacks upgraded shares of Gamco Investors (NYSE:GBL) from an underperform rating to a neutral rating in a research note released on Monday morning. They currently have $84.60 target price on the stock. On last trading day GAMCO Investors, Inc. (NYSE:GBL) fell -1.88% to close at $83.56. Its volatility for the week is 2.89% while volatility for the month is 2.64%. GBL’s sales growth for past 5 years was 10.20% and its EPS growth for past 5 years was 38.50%. GAMCO Investors, Inc. (NYSE:GBL) monthly performance is -5.03%.